Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jotam G Pasipanodya

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Diagnostics (Basel, Switzerland)|August 27, 2021
Comparative Effectiveness of Methotrexate versus Methylprednisolone in Treatment Naïve Pulmonary Sarcoidosis PatientsJotam G Pasipanodya
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 2, 2013
Reply to Moonan and Weis, Seaworth et al, and Nunn and PhillipsJotam G Pasipanodya, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy|May 5, 2010
Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently usedJotam G Pasipanodya, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2013
A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patientsJotam G Pasipanodya, Tawanda Gumbo
American Journal of Respiratory and Critical Care Medicine|March 5, 2013
Drug concentration monitoring in Mycobacterium avium lung disease: problems with methods and conclusionsJotam G Pasipanodya, Tawanda Gumbo
Current Opinion in Pharmacology|August 3, 2011
A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugsJotam G Pasipanodya, Tawanda Gumbo
The Lancet. Child & Adolescent Health|July 21, 2019
Dosing tuberculosis drugs in young children: the road aheadJotam G Pasipanodya, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 8, 2018
Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?Jotam G Pasipanodya, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2020
The Relationship Between Drug Concentration in Tuberculosis Lesions, Epithelial Lining Fluid, and Clinical OutcomesJotam G Pasipanodya, Tawanda Gumbo
Health and Quality of Life Outcomes|January 21, 2010
Measuring health-related quality of life in tuberculosis: a systemic review--responseStephen E Weis, Jotam G Pasipanodya
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Diagnostics (Basel, Switzerland)|August 27, 2021
Comparative Effectiveness of Methotrexate versus Methylprednisolone in Treatment Naïve Pulmonary Sarcoidosis PatientsJotam G Pasipanodya
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 2, 2013
Reply to Moonan and Weis, Seaworth et al, and Nunn and PhillipsJotam G Pasipanodya, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy|May 5, 2010
Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently usedJotam G Pasipanodya, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2013
A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patientsJotam G Pasipanodya, Tawanda Gumbo
American Journal of Respiratory and Critical Care Medicine|March 5, 2013
Drug concentration monitoring in Mycobacterium avium lung disease: problems with methods and conclusionsJotam G Pasipanodya, Tawanda Gumbo
Current Opinion in Pharmacology|August 3, 2011
A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugsJotam G Pasipanodya, Tawanda Gumbo
The Lancet. Child & Adolescent Health|July 21, 2019
Dosing tuberculosis drugs in young children: the road aheadJotam G Pasipanodya, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 8, 2018
Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?Jotam G Pasipanodya, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2020
The Relationship Between Drug Concentration in Tuberculosis Lesions, Epithelial Lining Fluid, and Clinical OutcomesJotam G Pasipanodya, Tawanda Gumbo
Health and Quality of Life Outcomes|January 21, 2010
Measuring health-related quality of life in tuberculosis: a systemic review--responseStephen E Weis, Jotam G Pasipanodya
Pageof 9